FCCC LOGO Faculty Publications
Hall MJ , Ruth KJ , Chen DY , Gross LM , Giri VN
Interest in genomic SNP testing for prostate cancer risk: a pilot survey
Hered Cancer Clin Pract. 2015 ;13(1) :11
PMID: 25874018    PMCID: PMC4396119    URL: http://www.ncbi.nlm.nih.gov/pubmed/25874018
Back to previous list
BACKGROUND: Advancements in genomic testing have led to the identification of single nucleotide polymorphisms (SNPs) associated with prostate cancer. The clinical utility of SNP tests to evaluate prostate cancer risk is unclear. Studies have not examined predictors of interest in novel genomic SNP tests for prostate cancer risk in a diverse population. METHODS: Consecutive participants in the Fox Chase Prostate Cancer Risk Assessment Program (PRAP) (n = 40) and unselected men from surgical urology clinics (n = 40) completed a one-time survey. Items examined interest in genomic SNP testing for prostate cancer risk, knowledge, impact of unsolicited findings, and psychosocial factors including health literacy. RESULTS: Knowledge of genomic SNP tests was low in both groups, but interest was higher among PRAP men (p < 0.001). The prospect of receiving unsolicited results about ancestral genomic markers increased interest in testing in both groups. Multivariable modeling identified several predictors of higher interest in a genomic SNP test including higher perceived risk (p = 0.025), indicating zero reasons for not wanting testing (vs >/=1 reason) (p = 0.013), and higher health literacy (p = 0.016). CONCLUSIONS: Knowledge of genomic SNP testing was low in this sample, but higher among high-risk men. High-risk status may increase interest in novel genomic tests, while low literacy may lessen interest.
Hall, Michael J Ruth, Karen J Chen, David Yt Gross, Laura M Giri, Veda N eng Poland 2015/04/16 06:00 Hered Cancer Clin Pract. 2015 Apr 8;13(1):11. doi: 10.1186/s13053-015-0032-3. eCollection 2015.